OTCPK:BUENF - Post by User
Comment by
minedrilleron Jan 25, 2021 7:29am
116 Views
Post# 32373332
RE:BELLUS Health to Present - 11th Int. Cough Symposium
RE:BELLUS Health to Present - 11th Int. Cough SymposiumGood point "but" (do your DD) ... Extremely promising, there is zero excuse for them to get this wrong. There is no intrinisc way they could mess this up unless they purposely intend to do so. Virtually all the work for BLU-5937 with regards to chronic cough has been completed already in Phase 2. Phase 2b is refining the primary end point (through altering Baseline Characteristics and demographics etc) - they know exactly and precisely what they want to achieve (or at the very very least SHOULD!). Statements from Bellus Health on the 01/22/2021 such as: 1. "Previous studies with a P2X3 antagonist had reported a statistically significant interaction between the cough frequency at baseline and treatment effect," 2. "A significant interaction was seen between baseline cough frequency and the primary efficacy outcome" and 3. "The observed statistically significant interaction between baseline cough frequency and treatment effect demonstrates the importance of considering baseline cough frequency in the design of future clinical trials," are stating that they have discovered a particular and viable market niche which their product fits perfectly. To reiterate, they blow this and the book will be well and truly thrown at them.